- VELCADE(R) (bortezomib) for Injection sales grew 20% to $265 million in
2007- - sNDA submitted for VELCADE expansion into front-line multiple myeloma - - MLN0002 core bridging studies fully enrolled, showing favorable results -
- New proteasome inhibitor, MLN2238, enters development pipeline -
- On track to exceed 2007 net income financial guidance -
CAMBRIDGE, Mass., Jan. 4 /PRNewswire-FirstCall/ -- Building on a record year in 2007, Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced 2008 corporate goals and financial guidance. These goals, along with selected financial and operational results from 2007, will be presented at the 26th Annual JPMorgan Healthcare Conference on January 9, 2008, in San Francisco, Calif.
"The past year was the most successful in the Company's 15-year history with outstanding accomplishments across commercial, R&D and operations. Millennium is well positioned for strong growth in 2008 and beyond," said Deborah Dunsire, M.D., President and Chief Executive Officer, Millennium. "The expected launch in front-line multiple myeloma is the next catalyst for VELCADE. Our late-stage product candidate, MLN0002, is approaching pivotal trials in inflammatory bowel diseases, representing the next revenue growth driver, and our innovative R&D organization continues to fuel the pipeline. We begin 2008 in the strongest financial position in the Company's history and remain firmly committed to continued top- and bottom-line growth."
In 2008, the Company's goals will focus on three strategic
|SOURCE Millennium Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved